The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...

Johnson & Johnson (JNJ) stock is in focus as the company's experimental therapy for systemic lupus erythematosus hits the ...

Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic lupus erythematosus (SLE) and the initiation of a ...

A motorcyclist died after an accident with a car in the early hours of Tuesday (Jan 6) on the Seletar Expressway (SLE).A ...

The police said that a 48-year-old male car driver is assisting with investigations. Read more at straitstimes.com. Read more ...

Johnson & Johnson said it will initiate a Phase 3 trial of its treatment for systemic lupus erythematosus, or SLE, after a recent study of the therapy met its primary endpoint.

Scottish Land & Estates warns rural Scotland needs urgent investment in storm resilience to protect communities and businesses from ...

Under normal conditions, cytokines aid in pathogen recognition and elimination while contributing to immune system ...

The police and the Singapore Civil Defence Force said in response to queries that they were alerted to the accident involving ...

Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

Subcutaneous anifrolumab significantly reduces disease activity in patients with moderate to severe systemic lupus erythematosus.

In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...